These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 26212223)
1. Primary biliary cirrhosis: safety and benefits of established and emerging therapies. Tabibian JH; Lindor KD Expert Opin Drug Saf; 2015; 14(9):1435-44. PubMed ID: 26212223 [TBL] [Abstract][Full Text] [Related]
2. Obeticholic acid for the treatment of primary biliary cholangitis. Ali AH; Lindor KD Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093 [TBL] [Abstract][Full Text] [Related]
3. Emerging drugs for the treatment of Primary Biliary Cholangitis. Ali AH; Tabibian JH; Carey EJ; Lindor KD Expert Opin Emerg Drugs; 2016; 21(1):39-56. PubMed ID: 26901615 [TBL] [Abstract][Full Text] [Related]
4. Investigational drugs in phase II clinical trials for primary biliary cholangitis. Silveira MG; Lindor KD Expert Opin Investig Drugs; 2017 Oct; 26(10):1115-1121. PubMed ID: 28836457 [TBL] [Abstract][Full Text] [Related]
5. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Holtmeier J; Leuschner U Digestion; 2001; 64(3):137-50. PubMed ID: 11786661 [TBL] [Abstract][Full Text] [Related]
6. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512 [TBL] [Abstract][Full Text] [Related]
7. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. Babatin MA; Sanai FM; Swain MG Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885 [TBL] [Abstract][Full Text] [Related]
8. Emerging drugs for the treatment of primary biliary cholangitis. Phaw NA; Dyson JK; Jones D Expert Opin Emerg Drugs; 2020 Jun; 25(2):101-112. PubMed ID: 32253941 [TBL] [Abstract][Full Text] [Related]
9. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401 [TBL] [Abstract][Full Text] [Related]
10. Current and promising therapy for primary biliary cholangitis. Gossard AA; Lindor KD Expert Opin Pharmacother; 2019 Jun; 20(9):1161-1167. PubMed ID: 30931642 [TBL] [Abstract][Full Text] [Related]
17. Primary biliary cirrhosis and bile acids. Corpechot C Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888 [TBL] [Abstract][Full Text] [Related]
18. Recurrent primary biliary cirrhosis after liver transplantation--the disease and its management. Schreibman I; Regev A MedGenMed; 2006 May; 8(2):30. PubMed ID: 16926769 [TBL] [Abstract][Full Text] [Related]
19. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Myers RP; Swain MG; Lee SS; Shaheen AA; Burak KW Am J Gastroenterol; 2013 Jun; 108(6):933-41. PubMed ID: 23649186 [TBL] [Abstract][Full Text] [Related]
20. New Treatment Paradigms in Primary Biliary Cholangitis. Levy C; Manns M; Hirschfield G Clin Gastroenterol Hepatol; 2023 Jul; 21(8):2076-2087. PubMed ID: 36809835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]